Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about SMO: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
| Gene Symbol | SMO |
| Full Name | Smoothened, Frizzled Class Receptor |
| Chromosome | 7q32.1 |
| Protein Type | Receptor |
| Function | encodes a 793 amino acid class F G protein-coupled receptor (GPCR) that serves as the essential signal transducer of the Hedgehog (Hh) signaling pathway. |
| Primary Expression | neural progenitor cells of the ventricular zone, the external granular layer of the cerebellum, and the subventricular zone (SVZ) |
| Amino Acids | 793 aa |
| Exons | 12 |
| Pathways | Apoptosis, Hedgehog |
| Ensembl ID | ENSG00000128602 |
| GeneCards | SMO |
| Human Protein Atlas | SMO |
| Gαi coupling | SMO activates heterotrimeric Gi proteins, reducing cAMP and modulating PKA activity independently of GLI |
| Ca²⁺ signaling | SMO-Gαi coupling triggers phospholipase C (PLC) activation and inositol trisphosphate (IP3)-dependent Ca²⁺ release from the ER |
| Small GTPases | SMO activates RhoA and Rac1 to regulate cytoskeletal dynamics, growth cone guidance, and axonal pathfinding |
| Associated Diseases | ALS, Ameloblastoma, Cancer, Carcinoma, Medulloblastoma |
| Interactions | APOPTOSIS, BCL2, CANCER, GLI1, GLI2, SHH |
| KG Connections | 64 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
Knowledge base pages for this entity
graph TD
SMO["SMO"]
AMELOBLASTOMA{"AMELOBLASTOMA"}
SMO -->|"associated with"| AMELOBLASTOMA
Ms{"Ms"}
SMO -->|"therapeutic target"| Ms
Apoptosis(["Apoptosis"])
SMO -->|"therapeutic target"| Apoptosis
Angiogenesis(["Angiogenesis"])
SMO -->|"therapeutic target"| Angiogenesis
GENES["GENES"]
SMO -->|"therapeutic target"| GENES
SMO -->|"contributes to"| Apoptosis
SMO -->|"contributes to"| Angiogenesis
APOPTOSIS["APOPTOSIS"]
SMO -->|"contributes to"| APOPTOSIS
BRAF["BRAF"]
SMO -->|"expressed in"| BRAF
neurodegeneration["neurodegeneration"]
SMO -->|"implicated in"| neurodegeneration
BRAF -->|"therapeutic target"| SMO
BRAF -->|"expressed in"| SMO
APOPTOSIS -->|"contributes to"| SMO
GENES -->|"expressed in"| SMO
AND["AND"]
AND -->|"expressed in"| SMO
style SMO fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0| Target | Relation | Type | Str |
|---|---|---|---|
| AMELOBLASTOMA | associated_with | disease | 0.85 |
| Ameloblastoma | associated_with | disease | 0.85 |
| Hedgehog | therapeutic_target | pathway | 0.80 |
| Als | therapeutic_target | disease | 0.75 |
| Cancer | therapeutic_target | disease | 0.75 |
| Sonic Hedgehog | therapeutic_target | pathway | 0.70 |
| Carcinoma | therapeutic_target | disease | 0.65 |
| Tumor | therapeutic_target | disease | 0.65 |
| Medulloblastoma | implicated_in | disease | 0.65 |
| Ms | therapeutic_target | disease | 0.65 |
| Cancer | implicated_in | disease | 0.65 |
| Carcinoma | implicated_in | disease | 0.65 |
| Cancer | activates | disease | 0.65 |
| Tumor | activates | disease | 0.65 |
| Prostate Cancer | therapeutic_target | disease | 0.65 |
| Carcinoma | inhibits | disease | 0.65 |
| Colorectal Cancer | activates | disease | 0.65 |
| APOPTOSIS | therapeutic_target | gene | 0.60 |
| GENES | expressed_in | gene | 0.60 |
| GENES | therapeutic_target | gene | 0.60 |
| Apoptosis | contributes_to | pathway | 0.60 |
| Angiogenesis | contributes_to | pathway | 0.60 |
| Apoptosis | activates | pathway | 0.60 |
| Hedgehog | activates | pathway | 0.60 |
| Akt | therapeutic_target | pathway | 0.60 |
| Raf | therapeutic_target | protein | 0.60 |
| APOPTOSIS | contributes_to | gene | 0.60 |
| AND | expressed_in | gene | 0.60 |
| GLI2 | activates | gene | 0.60 |
| BRAF | expressed_in | gene | 0.60 |
| Apoptosis | therapeutic_target | pathway | 0.60 |
| Angiogenesis | therapeutic_target | pathway | 0.60 |
| Hedgehog | implicated_in | pathway | 0.60 |
| Wnt | therapeutic_target | pathway | 0.60 |
| Invasion | therapeutic_target | pathway | 0.60 |
| Stem Cell | therapeutic_target | pathway | 0.60 |
| Tumor Microenvironment | therapeutic_target | pathway | 0.60 |
| Immunotherapy | therapeutic_target | pathway | 0.60 |
| ALS | associated_with | disease | 0.60 |
| EZH2 | therapeutic_target | gene | 0.60 |
| BRAF | therapeutic_target | gene | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| genes-smo | linked_to | wiki_page | 1.00 |
| BRAF | therapeutic_target | gene | 0.70 |
| CANCER | therapeutic_target | gene | 0.70 |
| APOPTOSIS | therapeutic_target | gene | 0.60 |
| BCL2 | activates | gene | 0.60 |
| SHH | inhibits | gene | 0.60 |
| GLI1 | activates | gene | 0.60 |
| APOPTOSIS | activates | gene | 0.60 |
| CANCER | activates | gene | 0.60 |
| WNT | therapeutic_target | gene | 0.60 |
| BRD4 | therapeutic_target | gene | 0.60 |
| BAD | therapeutic_target | gene | 0.60 |
| DES | therapeutic_target | gene | 0.60 |
| BRAF | implicated_in | gene | 0.60 |
| AND | therapeutic_target | gene | 0.60 |
| APOPTOSIS | contributes_to | gene | 0.60 |
| GENES | expressed_in | gene | 0.60 |
| CANCER | implicated_in | gene | 0.60 |
| BRAF | expressed_in | gene | 0.60 |
| SHH | therapeutic_target | gene | 0.60 |
| MYC | co_expressed_with | gene | 0.50 |
| SHH | co_expressed_with | gene | 0.50 |
| BRAF | co_expressed_with | gene | 0.50 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Osmotic Gradient Restoration via Selective AQP1 Enhancement | 0.680 | neurodegeneration | Perivascular spaces and glymphatic clear |
| Lysosomal Accumulation-Induced V-ATPase Inhibition (Osmotic | 0.470 | neurodegeneration | Why do structurally diverse sugars (treh |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.900 | 0.50 | aortic endothelial cells | proposed | $6,550,000 |
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| AQP1 differentially orchestrates endothelial cell senescence. [PMID:39180980] | Shabanian K, Shabanian T, Karsai G, Pont | Redox Biol | 2024 | 1 |
| Non-Aquaporin Water Channels. [PMID:36717505] | Huang B, Wang H, Yang B | Adv Exp Med Biol | 2023 | 1 |
| Aquaporins in Nervous System. [PMID:28258567] | Xu M, Xiao M, Li S, Yang B | Adv Exp Med Biol | 2017 | 1 |
| Aquaporins in the Spinal Cord. [PMID:27941618] | Oklinski MK, Skowronski MT, Skowronska A | Int J Mol Sci | 2016 | 1 |
| Aquaporin gating. [PMID:16837191] | Hedfalk K, Törnroth-Horsefield S, Nyblom | Curr Opin Struct Biol | 2006 | 1 |
| Panax notoginseng saponins protect the blood-brain barrier against oxidative str [PMID:41763432] | Fan L, Qu S, Miao C, Wu D, Rao Y et al. | Int J Biol Macromol | 2026 | 0 |
| Stomatin encapsulates aquaporin-1 and urea transporter-B in the erythrocyte memb [PMID:41921000] | Vallese F, Li H, Barazzuol L, Calì T, Cl | Sci Adv | 2026 | 0 |
| Aquaporin membrane channels in the hepatobiliary tract: a model of complexity an [PMID:41926019] | Portincasa P, Khalil M, Calamita G | Intern Emerg Med | 2026 | 0 |
| Glycosomal Aquaglyceroporin 1 dual role in iron homeostasis and antimony suscept [PMID:41926379] | Boy RL, Zampieri RA, Aoki JI, Coelho AC, | PLoS Negl Trop Dis | 2026 | 0 |
| Aquaporin-1 Facilitates Macrophage M1 Polarization by Enhancing Glycolysis Throu [PMID:39365391] | ["Diao R", "Lv W", "Wang Y", "Shen Q", " | Inflammation | 2025 | 0 |
| Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acid [PMID:40533746] | ["Sanadgol N", "Abedi M", "Hashemzaei M" | Journal of nanobiotechnology | 2025 | 0 |
| AQP1 Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis. [PMID:34670044] | Morelle J, Marechal C, Yu Z, Debaix H, C | The New England journal of med | 2021 | 0 |
| Discovery of novel diarylamides as orally active diuretics targeting urea transp [PMID:33532188] | ["Zhang S", "Zhao Y", "Wang S", "Li M", | Acta pharmaceutica Sinica. B | 2021 | 0 |
| Physiological and pathological impact of AQP1 knockout in mice. [PMID:31023968] | Hua Y, Ying X, Qian Y, Liu H, Lan Y, Xie | Bioscience reports | 2019 | 0 |
| The potential role of aquaporin 1 on aristolochic acid I induced epithelial mese [PMID:29215709] | ["Li J", "Zhang M", "Mao Y", "Li Y", "Zh | Journal of cellular physiology | 2018 | 0 |
| Cardiotrophin-1 predicts death or heart failure following acute myocardial infar [PMID:17045183] | ["Khan S", "Kelly D", "Quinn P", "Davies | Journal of cardiac failure | 2006 | 0 |
| Regulation of mitosis in response to damaged or incompletely replicated DNA requ [PMID:16079276] | ["Purdy A", "Uyetake L", "Cordeiro M", " | Journal of cell science | 2005 | 0 |
| Physiological roles of aquaporins in the choroid plexus. [PMID:15949534] | Boassa D, Yool AJ | Current topics in developmenta | 2005 | 0 |
| Structural basis of ion pumping by Ca2+-ATPase of the sarcoplasmic reticulum. [PMID:15189143] | ["Toyoshima C", "Inesi G"] | Annual review of biochemistry | 2004 | 0 |
| Su e of the yeast F1Fo-ATP synthase forms homodimers. [PMID:12377768] | ["Brunner S", "Everard-Gigot V", "Stuart | The Journal of biological chem | 2002 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning SMO in their description or question text
No additional research found